Managed problem solving for antiretroviral therapy adherence: A randomized trial

JAMA Internal Medicine

Volumn 173, Issue 4, 2013, Pages 300-306

  Gross, Robert ^a,b,c   Bellamy, Scarlett L ^a   Chapman, Jennifer ^a   Han, Xiaoyan ^a   O'Duor, Jacqueline ^a,c   Palmer, Steven C ^b   Houts, Peter S ^d   Coyne, James C ^b,e   Strom, Brian L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d PENN STATE COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FOSAMPRENAVIR PLUS RITONAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR PLUS TIPRANAVIR;

ADULT; AGED; ANTIRETROVIRAL THERAPY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MANAGED PROBLEM SOLVING; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROBLEM SOLVING; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INTENTION TO TREAT ANALYSIS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT COMPLIANCE; PHILADELPHIA; PROBLEM SOLVING; SINGLE-BLIND METHOD; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84874851321     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2013.2152     Document Type: Article

References (40)

1. Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther. 2011;33 (1): 74-109.
2. Pittman DG, Tao Z, Chen W, Stettin GD. Antihypertensive medication adherence and subsequent healthcare utilization and costs. Am J Manag Care. 2010;16 (8): 568-576.
3. Chan DC, Shrank WH, Cutler D, et al. Patient, physician, and payment predictors of statin adherence. Med Care. 2010;48 (3): 196-202.
4. Gross R, Yip B, Lo Re V III, et al. A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis. 2006;194 (8): 1108-1114.
5. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160 (14): 2101-2107.
6. Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27 (3): 251-259.
7. Bangsberg DR, Ragland K, Monk A, Deeks SG. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS. 2010;24 (18): 2835-2840.
8. Harris J, Pillinger M, Fromstein D, et al. Risk factors for medication nonadherence in an HIV infected population in the Dominican Republic. AIDS Behav. 2011;15 (7): 1410-1415.
9. Graham J, Bennett IM, Holmes WC, Gross R. Medication beliefs as mediators of the health literacy-antiretroviral adherence relationship in HIV-infected individuals. AIDS Behav. 2007;11 (3): 385-392.
10. Kalichman SC, Ramachandran B, Catz S. Adherence to combination antiretroviral therapies in HIV patients of low health literacy. J Gen Intern Med. 1999; 14 (5): 267-273.
11. Higgins N, Regan C. A systematic review of the effectiveness of interventions to help older people adhere to medication regimes. Age Ageing. 2004;33 (3): 224- 229.
12. Simoni JM, Amico KR, Pearson CR, Malow R. Strategies for promoting adherence to antiretroviral therapy: a review of the literature. Curr Infect Dis Rep. 2008; 10 (6): 515-521.
13. Bain-Brickley D, Butler LM, Kennedy GE, Rutherford GW. Interventions to improve adherence to antiretroviral therapy in children with HIV infection. Cochrane Database Syst Rev. 2011;12 (12): CD009513.
14. Nezu AM, Nezu CM, Perri MG. Problem-Solving Therapy for Depression: Theory, Research, and Clinical Guidelines. New York, NY: John Wiley & Sons; 1989: 274.
15. D'Zurilla TJ, Nezu AM. Problem-solving therapies. In: Dobson KS, ed. Handbook of Cognitive-Behavioral Therapies. 2nd ed. New York, NY: The Guilford Press; 2001:211-245.
16. Hill-Briggs F, Gemmell L. Problem solving in diabetes self-management and control: a systematic review of the literature. Diabetes Educ. 2007;33 (6): 1032- 1050.
17. Nezu AM, Nezu CM, Felgoise SH, McClure KS, Houts PS. Project Genesis: assessing the efficacy of problem-solving therapy for distressed adult cancer patients. J Consult Clin Psychol. 2003;71 (6): 1036-1048.
18. Nezu CM, Nezu AM, Houts PS. Multiple applications of problem-solving principles in clinical practice. In: Kuehlwein KT, ed. Cognitive Therapies in Action: Evolving Innovative Practice. San Francisco, CA: Jossey-Bass Inc; 1993:353- 378.
19. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14 (4): 357-366.
20. Gross R, Bilker WB, Friedman HM, Strom BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS. 2001;15 (16): 2109- 2117.
21. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr. 2006;43 (1): 78-84.
22. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133 (1): 21-30.
23. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 × 10 (9) cells/L. Ann Intern Med. 2003;139 (10): 810-816.
24. Cohen MS, Chen YQ, McCauley M, et al HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365 (6): 493-505.
25. Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS. 2006;20 (2): 223-231.
26. Liu H, Miller LG, Hays RD, et al. Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. J Acquir Immune Defic Syndr. 2006;41 (3): 315-322.
27. Radloff L. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1 (3): 385-401.
28. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons With Harmful Alcohol Consumption, II. Addiction. 1993;88 (6): 791-804.
29. McLellan AT, Kushner H, Metzger D, et al. The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat. 1992;9 (3): 199-213.
30. Zeger SL, Liang KY. An overview of methods for the analysis of longitudinal data. Stat Med. 1992;11 (14-15): 1825-1839.
31. de Bruin M, Hospers HJ, van Breukelen GJ, Kok G, Koevoets WM, Prins JM. Electronic monitoring-based counseling to enhance adherence among HIVinfected patients: a randomized controlled trial. Health Psychol. 2010;29 (4): 421-428.
32. Lester RT, Ritvo P, Mills EJ, et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet. 2010;376 (9755): 1838-1845.
33. Ford N, Nachega JB, Engel ME, Mills EJ. Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials. Lancet. 2009; 374 (9707): 2064-2071.
34. Gross R, Tierney C, Andrade A, et al; AIDS Clinical Trials Group A5073 Study Team. Modified directly observed antiretroviral therapy compared with selfadministered therapy in treatment-naive HIV-1-infected patients: a randomized trial. Arch Intern Med. 2009;169 (13): 1224-1232.
35. Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIVinfected drug users: a prospective, randomized, controlled trial. Clin Infect Dis. 2007;45 (6): 770-778.
36. Simoni JM, Huh D, Frick PA, et al. Peer support and pager messaging to promote antiretroviral modifying therapy in Seattle: a randomized controlled trial. J Acquir Immune Defic Syndr. 2009;52 (4): 465-473.
37. Choudhry NK, Avorn J, Glynn RJ, et al Post-Myocardial Infarction Free Rx Event and Economic Evaluation (MI FREEE) Trial. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365 (22): 2088-2097.
38. Koenig LJ, Pals SL, Bush T, Pratt Palmore M, Stratford D, Ellerbrock TV. Randomized controlled trial of an intervention to prevent adherence failure among HIV-infected patients initiating antiretroviral therapy. Health Psychol. 2008; 27 (2): 159-169.
39. Goldie SJ, Paltiel AD, Weinstein MC, et al. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med. 2003;115 (8): 632-641.
40. Bisson GP, Rowh A, Weinstein R, Gaolathe T, Frank I, Gross R. Antiretroviral failure despite high levels of adherence: discordant adherence-response relationship in Botswana. J Acquir Immune Defic Syndr. 2008;49 (1): 107-110.